Adrià Closa

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia.

This paper identifies a synergistic combination of RNA Polymerase I inhibitor CX-5461 and CDK inhibitor Dinaciclib that enhances therapeutic efficacy in AML by inducing nucleolar stress and cell cycle arrest.

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies.

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

Extensive post-transcriptional buffering of gene expression in the response to oxidative stress in baker yeast

The paper compares RNA-Seq and Ribo-Seq for gene expression analysis under oxidative stress in baker's yeast, finding Ribo-Seq better correlates with protein abundance.